TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01225458

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: shorter tests
Description: Geriatric evaluation with MMS, GDS and ADL scoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shorter tests
Description: Geriatric evaluation with MMS, GDS and ADL scoring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: initial complete geriatric tests
Description: evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: initial complete geriatric tests
Description: evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up complete geriatric tests
Description: evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
Study: NCT00620191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg twice a day titrated from 500 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
Study: NCT04435652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: 3mg/kg, D1,8,15,Q4w, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: 3mg/kg, D1,8,15,Q4w, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100mg/m2, D1,8,15,Q4w, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100mg/m2, D1,8,15,Q4w, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2, D1,8,15,Q4w, IV infusion
Study: NCT04208061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Participants will receive single dose of dabigatran etexilate orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Participants will receive single dose of dabigatran etexilate orally.
Study: NCT03210961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 tablet
Description: PF-06826647 tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 oral suspension
Description: PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution/suspension
Description: placebo oral solution for the single ascending dose, first cohort only

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Matching placebo tablet
Study: NCT03956212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 7 days
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 14 days
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
Study: NCT01695434

Intervention type: OTHER
Intervention: MRI
Description: All subjects will undergo a MRI.

Intervention type: OTHER
Intervention: MRI
Description: All subjects will undergo a MRI.
Study: NCT04208061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI
Description: Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive ritonavir orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive Darunavir orally.
Study: NCT01890876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking uphill
Description: ascending about 500 m

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking uphill
Description: ascending about 500 m

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking downhill
Description: descending about 500 m

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking downhill
Description: descending about 500 m
Study: NCT03598712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression by chest bandage urgo K2®
Description: 1. - Installation of a short stretch belt (urgo K2® kit)~2. - Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. - Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punctures
Description: Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
Study: NCT02008344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: favipiravir
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.~* Day 1: 1800 mg twice daily (loading doses)~* Days 2 through 5: 800 mg twice daily
Study: NCT02509845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: Antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: Antimicrobial peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2
Description: Antimicrobial peptide
Study: NCT03598712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: punctures
Description: Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
Study: NCT02509845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00735722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU AF Ablation
Description: Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
Study: NCT04457063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PKP
Description: 1. The horizontal axis was marked with a pointed marker at the slit lamp immediately before surgery.~2. TICL loading into the STAAR injector cartridge~3. Temporal clear corneal 3 mm incision \& 2-side ports then viscoelastic injection into the AC~4. Implantation of the TICL using the injector, then rotation according to the implantation diagram guided with Mendez protractor, and lastly placement of the haptics under the iris.~5. Pupil constriction with A.Ch.~6. Washing the viscoelastic \&Wound hydration.~7. Topical antibiotic steroids (Vigamox and Tobradex) 4 times /day for 3weeks
Study: NCT02645292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mile walk using treadmill
Description: Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stair Climbing
Description: Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
Study: NCT02798978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
Study: NCT00301418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
Study: NCT00772265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin N
Description: Total Dose per subject will be 0.4IU/Kg given Subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novolin N
Description: Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
Study: NCT02175979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enriched enteral nutrition
Description: enriched enteral tube feeding perioperative

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard
Description: standard of care
Study: NCT03320980

Intervention type: PROCEDURE
Intervention: RALPPS
Description: RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage

Intervention type: PROCEDURE
Intervention: portal vein embolization + major liver resection
Description: PVE on the first stage and major liver resection on the second stage
Study: NCT03320031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Take linagliptin 5mg a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog Mix 75/25
Description: Administer subcutaneous premixed insulin twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix 75/25
Description: Administer subcutaneous premixed insulin twice a day.
Study: NCT03417245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fitusiran
Description: by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: factor concentrates
Description: by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: factor concentrates
Description: by intravenous (IV) injection
Study: NCT00544778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00118560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: treadmill walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical walking
Description: calf muscle exercise
Study: NCT04096924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidewire for echo-guided interventions
Description: Under echocardiography guided treatment of ASD with a novel interventional guidewire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook lunderquist guidewire
Description: Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
Study: NCT02334293

Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven
Description: Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
Study: NCT04111913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: anlotinib once daily on days 1-14 of 21days cycle.
Study: NCT03679117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
Study: NCT03030131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 750 mg IV Day1, 15, 29
Study: NCT01220817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 POMx capsules
Description: 3 POMx capsules daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 POMx capsule
Description: 1 POMx capsule daily
Study: NCT00198107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
Study: NCT02672475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02067728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FNPA tool
Description: Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
Study: NCT03660657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
Study: NCT04942951

Intervention type: DIAGNOSTIC_TEST
Intervention: Gynecological examination
Description: Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gynecological examination
Description: Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.

Intervention type: OTHER
Intervention: Pelvic Organ Prolapse Quantification (POP-Q)
Description: Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.

Intervention type: OTHER
Intervention: Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire
Description: ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.

Intervention type: OTHER
Intervention: Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire
Description: PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.

Intervention type: OTHER
Intervention: Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire
Description: PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
Study: NCT03495102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study: NCT00967356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5985
Description: Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT01509638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 Standard of Care
Description: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 EXPAREL
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
Study: NCT03166891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Take 50mg orally once daily
Study: NCT00494234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Participants will receive capsules of olaparib orally as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Participants will receive capsules of olaparib orally as stated in arm description.
Study: NCT01980056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle